About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting

By: via Business Wire

CareDx Highlights Latest Innovations in HLA Typing and Hematopoietic Stem Cell Transplant Chimerism Monitoring

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading presence as a Diamond Level sponsor at the 48th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in Las Vegas, Nevada from October 24 to October 28.

“CareDx is proud to be a leading sponsor of this year’s ASHI meeting to help drive continued innovation in transplantation through our laboratory products,” said Reg Seeto, CEO and President of CareDx. “We are excited to share the latest data about our innovative, best-in-class NGS HLA typing kits and chimerism monitoring solutions for hematopoietic stem cell transplantation.”1

CareDx will be presenting the latest data on its AlloSeq NGS1 solutions and hosting a symposium, “Innovation Across the Pre- and Post-Transplant Journey,” on Tuesday, October 25, from 12:00 noon to 2:05 p.m. PT. Moderated by Curtis Lind, Vice President and Head of Research and Development Products at CareDx, the symposium includes the following:

  • NGS-HLA for Solid Organ Transplant: The Time is Now. Cathi Murphey Half, Ph.D., HCLD/CC(ABB), A(ACHI), Director, Histocompatibility and Immunogenetics Laboratory Southwest Immunodiagnostics, Inc.
  • NGS Chimerism Validation: The St. Jude Experience. Paula Arnold, Ph.D., D(ABHI), Technical Director, HLA Department of Pathology, St. Jude Children’s Research Hospital.

“I look forward to attending this year’s ASHI meeting and connecting with the HLA community to review the latest transplant innovations, including those developed by CareDx using next-generation sequencing and hybrid capture technologies,” said Cathi Murphey Half, Ph.D., HCLD/CC(ABB), A(ACHI) Director, Histocompatibility and Immunogenetics Laboratory Southwest Immunodiagnostics, Inc.

Eight scientific abstracts highlight the use of CareDx’s flagship AlloSeq Tx171, which offers laboratory professionals a novel method for matching transplant recipients and potential donors. The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies. By sequencing the HLA genes, better matches can be selected, giving transplanted organs a higher chance of long-term allograft survival.

Additionally, three abstracts highlight the validation and use of AlloSeq HCT.1 The data will highlight the performance and potential utility of a more streamlined, sensitive approach for NGS-based engraftment monitoring and surveillance following hematopoietic stem cell transplantation.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s leading presence and sponsorship in 2022 ASHI meeting (the “Meeting”), its AlloSeq products and solutions, and its presentation of the latest data on the AlloSeq products and solutions and transplant innovation at the Meeting (the “Presentation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its leading presence and sponsorship in the Meeting, its AlloSeq products and solutions, or its Presentation; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

References:

1. AlloSeq Tx17 and AlloSeq HCT are for research use only in the United States.

Contacts

More News

View More
Microsoft 365 Premium Marks the Next Phase of AI Monetization
Via MarketBeat
Topics Artificial Intelligence
Tickers MSFT
Could Target’s Week of Discounts Come Full Circle for Investors?
Via MarketBeat
Topics Economy
Tickers AAPL GE TGT WMT
3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings
Via MarketBeat
Tickers SFM
Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
Via MarketBeat
Tickers BSET ETD HVT
AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon
Via MarketBeat
Tickers ASTS JOBY RGTI T VOD VZ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.